MATTERHORN: phase III study of durvalumab plus FLOT . . . - PubMed We describe the rationale for and the design of MATTERHORN, a randomized, double-blind, placebo-controlled, phase III study investigating the efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy followed by adjuvant durvalumab monotherapy in patients with resectable gastric gastroesophageal junction cancer
MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant . . . The MATTERHORN trial is the first global phase 3 study to show a clear EFS benefit with immunotherapy in the perioperative setting for resectable GC GEJC Durvalumab plus FLOT significantly reduced the risk of recurrence or progression compared to standard FLOT alone
Imfinzi-based regimen demonstrated statistically significant and . . . MATTERHORN is a randomised, double-blind, placebo-controlled, multi-centre, global Phase III trial evaluating Imfinzi as perioperative treatment for patients with resectable Stage II-IVA gastric and GEJ cancers Perioperative therapy includes treatment before and after surgery, also known as neoadjuvant adjuvant therapy
MATTERHORN: Durvalumab + Chemotherapy Demonstrates Superior EFS Over . . . New results from the global, phase 3 MATTERHORN study show that perioperative durvalumab plus FLOT yields superior event-free survival over FLOT plus placebo in patients with resectable, early-stage gastric gastroesophageal junction cancer (LBA5)
Additional Analysis of MATTERHORN Confirms Global Benefit of Durvalumab . . . Subgroup analyses of the randomized double-blind phase III MATTERHORN trial continue to show the benefit of adding perioperative durvalumab to standard chemotherapy in patients with locally advanced, resectable gastric or gastroesophageal junction cancer
MATTERHORN Trial Shows Imfinzi Plus Chemotherapy Produces Significant . . . Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically significant event-free survival in a Phase III trial for resectable gastric and gastroesophageal junction cancers, signaling a potential shift in standard perioperative care
LBA73 Pathological complete response (pCR) to durvalumab plus 5 . . . The global, Phase 3, randomised, double-blind, placebo (P)-controlled MATTERHORN study (NCT04592913) assesses perioperative durvalumab (D) with FLOT in participants (pts) with resectable GC GEJC Results of a pre-planned interim analysis (IA) are reported